{"contentid": 488531, "importid": NaN, "name": "NovoBiome launched to \u00e2\u0080\u0098revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis\u00e2\u0080\u0099", "introduction": "The launch of French drug discovery company NovoBiome has been announced.", "content": "<p>The launch of French drug discovery company NovoBiome has been announced.</p>\n<p>NovoBiome, which is focused on the nexus of liver, intestinal diseases and the gut microbiome, has been launched by a team of experts in the fields of microbiology and artificial intelligence.</p>\n<p><span class=\"pullQuote\">\"We are well-positioned to become a leader in discovering next-generation gut-liver therapies\"</span>The company will develop breakthrough live biotherapeutics products (LBPs) targeting this axis while building a comprehensive, disruptive<em> ex-vivo</em> research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.</p>\n<p>NovoBiome&rsquo;s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato-hepatitis (NASH).</p>\n<p>NAFLD has become the most common cause of chronic liver diseases, and can lead to NASH, a more serious condition. Due to the growing epidemic of metabolic disorders with the development of Western lifestyles, the NASH market is rising rapidly and is expected to reach $18.3 billion by 2026 in the USA and Europe&rsquo;s five largest markets, a compound annual growth rate of 63% from 2016.</p>\n<p>ADC-001 comprises an anti-inflammatory bacterium, member of the class <em>Coriobacteriia</em> that has demonstrated potent therapeutic effects <em>in vitro</em> and in animal models. It is currently in development with the aim of entering human trials by 2022 to 2023.</p>\n<p>Pierre-Yves Mousset, chief executive of NovoBiome, said: &ldquo;The microbiome is a fast growing and disruptive field of research that has the potential to revolutionize the diagnosis, prevention and treatment of liver diseases.</p>\n<p>&ldquo;NovoBiome has been founded to exploit the broad potential of LBPs that target the critical microbiome-gut-liver axis. The role of gut bacteria in the large and growing NAFLD and NASH markets has been clearly documented and NovoBiome aims to provide the first ecosystem treatment approach.</p>\n<p>&ldquo;With a strong founding team, excellent science, best-in-class technologies and enthusiastic support from investors, we are well-positioned to become a leader in discovering next-generation gut-liver therapies.&rdquo;</p>", "date": "2021-05-04 14:18:00", "meta_title": NaN, "meta_keywords": "NovoBiome, liver, diseases, drug, discovery, treatment, launched, targeting, NASH, axis\u00e2\u0080\u0099, therapies, announced, French, company, launch, NAFLD, potential", "meta_description": "The launch of French drug discovery company NovoBiome has been announced.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-04 13:31:56", "updated": "2021-05-04 14:18:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/novobiome-launched-to-revolutionize-treatment-of-liver-diseases-by-targeting-the-microbiome-gut-liver-axis", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novobiome_large.png", "image2id": "novobiome_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Inflammatory diseases, Nephrology and Hepatology", "topic_tag": "Companies, mergers and acquisitions, Research", "geography_tag": "France", "company_tag": "NovoBiome", "drug_tag": "ADC-001", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 14:18:00"}